参考文献

［1］Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol [Internet].

2013:1-13. Available from:

http://informahealthcare.com/doi/pdf/10.1517/17425255.2013.791282［資料番号：5.4―1］

［2］Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515-31.［資料番号：5.4

―2］

［3］清野裕, 南條輝志男, 田嶼尚子, 門脇孝, 柏木厚典, 荒木栄一, 他. 糖尿病の分類と診断 基準に関する委員会報告（国際標準化対応版）. 糖尿病. 2012;55:485-504.［資料番号：5.4

―3］

［4］Global burden [Internet]. International Diabetes Federation. 2011 [cited 2013 May 7]. Available from: http://www.idf.org/diabetesatlas/5e/the-global-burden［資料番号：5.4―4］

［5］厚生労働省. 結果の概要, 第1 部 糖尿病等の状況. 平成19年国民健康・栄養調査報告 [Internet]. 2010:44-55. Available from:

http://www.mhlw.go.jp/bunya/kenkou/eiyou09/dl/01-kekka-01.pdf［資料番号：5.4―5］

［6］Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13(6):610-30.［資 料番号：5.4―6］

［7］Yki-Järvinen H. Glucose toxicity. Endocr Rev. 1992;13(3):415-31.［資料番号：5.4―7］

［8］Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet.

2010;375:2215-22.［資料番号：5.4―8］

［9］Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama study.

Diabetes. 1996;45(Suppl 3):S14-6.［資料番号：5.4―9］

［10］堀田饒, 中村二郎, 岩本安彦, 大野良之, 春日雅人, 吉川隆一, 他. アンケート調査によ る日本人糖尿病の死因 -1991～2000年の10年間. 18,385名での検討-. 糖尿病.

2007;50:47-61.［資料番号：5.4―10］

［11］日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン2010. 東京: 南江堂; 2010.［資料番号：5.4―11］

［12］Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.［資料番号：5.4―12］

［13］Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):

prospective observational study. BMJ. 2000;321:405-12.［資料番号：5.4―13］

［14］Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata Diabetes Study. Diabetes Care. 1999;22:920-4.［資料番号：5.4―14］

［15］日本糖尿病学会編. 糖尿病治療ガイド 2012-2013. 東京: 文光堂; 2012.［資料番号：5.4

―15］

［16］日本高血圧学会高血圧治療ガイドライン作成委員会編. 高血圧治療ガイドライン2009.

東京: ライフサイエンス出版; 2009.［資料番号：5.4―16］

［17］日本動脈硬化学会編. 動脈硬化性疾患予防ガイドライン2012年版. 東京: 杏林舎; 2012.

［資料番号：5.4―17］

［18］Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet.

2008;371:117-25.［資料番号：5.4―18］

［19］Li C, Ford ES, Tsai J, Zhao G, Balluz LS, Gidding SS. Serum non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular diseases among U.S. adults with

diagnosed diabetes: the third national health and nutrition examination survey linked mortality study. Cardiovasc Diabetol [Internet]. 2011 May 23;10:46. Available from:

http://www.cardiab.com/content/10/1/46［資料番号：5.4―19］

［20］Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994;93(1):397-404.［資料番号：5.4―20］

［21］Nomura S. Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent. Curr Top Med Chem. 2010;10(4):411-8.［資料番号：5.4―21］

［22］Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003;14(11):2873-82.

［資料番号：5.4―22］

［23］Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med.

2007;261:32-43.［資料番号：5.4―23］

［24］Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136-42.［資料番号：5.4― 24］

［25］Nair S, Wilding JPH. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95(1):34-42.［資料番号：5.4―25］

［26］DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5-14.［資料番号：

5.4―26］

［27］Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with

non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427-34.［資料番号：5.4―27］

［28］Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin on the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951;30(2):125-9.［資料番号：5.4―28］

［29］金井好克. 開発中の次世代の治療薬 SGLT阻害薬. Mebio. 2011;28(4):111-7.［資料番 号：5.4―29］

［30］Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally

controlled on insulin. Diabetes Obes Metab. 2012;14(6):539-45.［資料番号：5.4―30］

［31］UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.［資料番号：5.4―31］

［32］Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-17.［資料番号：5.4―32］

［33］Bohannon NJV. Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes Care.

1998;21:451-6.［資料番号：5.4―33］

［34］Lisboa C, Santos A, Dias C, Azevedo F, Pina-Vaz C, Rodrigues A. Candida balanitis: risk factors. J Eur Acad Dermatol Venereol. 2010;24:820-6.［資料番号：5.4―34］

［35］Chen SL, Jackson SL, Boyko EJ. Diabetes mellitus and urinary tract infection: epidemiology, pathogenesis and proposed studies in animal models. J Urol. 2009;182:S51-6.［資料番号：5.4

―35］

［36］Halprin KM, Ohkawara A, Adachi K. Glucose entry into the human epidermis: I. The concentration of glucose in the human epidermis. J Invest Dermatol. 1967;49:559-60.［資料番 号：5.4―36］

［37］Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk.

Diabetologia. 2005;48:1292-9.［資料番号：5.4―37］

［38］Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al.

Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31(5):845-51.［資料番号：5.4―38］

［39］Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009;169(15):1395-402.［資料番号：5.4―39］

［40］Reid IR. Relationships among body mass, its components, and bone. Bone. 2002;31:547-55.［資 料番号：5.4―40］

［41］Schwartz AV, Johnson KC, Kahn SE, Shepherd JA, Nevitt MC, Peters AL, et al. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial. J Bone Miner Res. 2012;27:619-27.［資料番号：5.4―41］

［42］Bleicher K, Cumming RG, Naganathan V, Travison TG, Sambrook PN, Blyth FM, et al. The role of fat and lean mass in bone loss in older men: findings from the CHAMP study. Bone.

2011;49:1299-305.［資料番号：5.4―42］

［43］Hinton PS, Rector RS, Linden MA, Warner SO, Dellsperger KC, Chockalingam A, et al.

Weight-loss-associated changes in bone mineral density and bone turnover after partial weight regain with or without aerobic exercise in obese women. Eur J Clin Nutr. 2012;66:606-12.［資料 番号：5.4―43］

［44］Hyldstrup L, Andersen T, McNair P, Breum L, Transbøl I. Bone metabolism in obesity: changes related to severe overweight and dietary weight reduction. Acta Endocrinol (Copenh).

1993;129:393-8.［資料番号：5.4―44］

［45］Shapses SA, Von Thun NL, Heymsfield SB, Ricci TA, Ospina M, Pierson RN Jr, et al. Bone turnover and density in obese premenopausal women during moderate weight loss and calcium supplementation. J Bone Miner Res. 2001;16(7):1329-36.［資料番号：5.4―45］

［46］Devine A, Dick IM, Dhaliwal SS, Naheed R, Beilby J, Prince RL. Prediction of incident osteoporotic fractures in elderly women using the free estradiol index. Osteoporos Int.

2005;16:216-21.［資料番号：5.4―46］

［47］Gonnelli S, Caffarelli C, Tanzilli L, Merlotti D, Gennari L, Rossi S, et al. The association of body composition and sex hormones with quantitative ultrasound parameters at the calcaneus and phalanxes in elderly women. Calcif Tissue Int. 2011;89(6):456-63.［資料番号：5.4―47］

［48］Kuchuk NO, van Schoor NM, Pluijm SMF, Smit JH, de Ronde W, Lips P. The association of sex hormone levels with quantitative ultrasound, bone mineral density, bone turnover and osteoporotic fractures in older men and women. Clin Endocrinol (Oxf). 2007;67:295-303.［資 料番号：5.4―48］

［49］Scholl-Bürgi S, Santer R, Ehrich JHH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant. 2004;19:2394-6.［資料番号：

5.4―49］

［50］Francis J, Zhang J, Farhi A, Carey H, Geller DS. A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrol Dial Transplant. 2004;19:2893-5.［資料番号：5.4

―50］

［51］Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733-94.［資料番号：5.4―51］

［52］Talley NJ, Jones M, Nuyts G, Dubois D. Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol. 2003;98:1107-11.［資料番号：5.4―52］

［53］Committees & Meeting Materials [Internet]. FDA briefing document. NDA 202293 Dapagliflozin tablets, 5 and 10 mg. Sponsor: Bristol-Myers Squibb. Advisory Committee Meeting. July 19, 2011. Available from: